: ? The FDA just removed 12 peptides (BPC157, TB500, Epitalon, GHKCu inj., DSIP, MOTSc, Semax, PEGMGF, Melanotan II, LL37, Dihexa, KPV) from Category 2 (donotcompound FDA Peptide Reclassification 2026: What Researchers Want Potential FDA Peptide Reclassification 2026 What It Means for Patients Beverly Hills Rejuvenation Center Save Peptides Save Peptides Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # The reason peptide access is changing comes down to two regulatory categories most patients don't know exist: 503A and 503B. 503A = traditional compounding pharmacies. State licensed, patient specific prescriptions. 503B = FDA registered outsourcing